Billionaire investor Ken Griffin increased his fund's stake in AbbVie Inc. by 547% [1] during the second quarter of 2026 [2].
The move signals a strong bet on the U.S. healthcare sector from one of the world's most prominent hedge fund managers. By targeting a high-yield dividend stock, Griffin is prioritizing consistent cash flow and value in a volatile market.
Griffin, the founder of Citadel LLC, purchased approximately 2.68 million shares [2] of the NYSE-listed company. The surge in holdings occurred throughout Q2 2026 [2], marking a significant expansion of his position in the pharmaceutical giant.
Market analysts said the investment is driven by AbbVie's status as a bargain. The company is recognized for its strong cash flow and high dividend yield [1]. This alignment suggests that Griffin views the current valuation as an entry point for long-term gains.
Wall Street analysts continue to rate the stock as a buy [1]. The consensus among these experts mirrors Griffin's apparent confidence in the company's financial stability and its ability to maintain payouts to shareholders.
AbbVie operates as a major player in the healthcare industry, focusing on specialty medicines. The decision to increase the stake by 547% [1] reflects a concentrated effort to leverage the company's dividend-paying capabilities, a strategy often used to hedge against broader market uncertainty.
“Ken Griffin increased his fund's stake in AbbVie Inc. by 547%”
This aggressive increase in holdings by Citadel suggests a shift toward 'value' investing within the healthcare space. By accumulating millions of shares in a dividend king, Griffin is positioning his portfolio to benefit from steady income streams while betting that the market has undervalued AbbVie's long-term cash flow potential.
